Roger A Edwards
Overview
Explore the profile of Roger A Edwards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hetland M, Strangfeld A, Bonfanti G, Soudis D, Deuring J, Edwards R
Arthritis Res Ther
. 2024 Aug;
26(1):153.
PMID: 39192350
Background: Patients with rheumatoid arthritis (RA) have an increased risk of developing serious infections (SIs) vs. individuals without RA; efforts to predict SIs in this patient group are ongoing. We...
2.
Thaci D, Tziotzios C, Ito T, Ko J, Karadag A, Fang H, et al.
Dermatol Ther (Heidelb)
. 2023 Sep;
13(11):2621-2634.
PMID: 37707764
Introduction: Ritlecitinib demonstrated efficacy in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study (NCT03732807). However, hair loss presentation may vary based on location (e.g., scalp, eyebrow/eyelash, body)....
3.
Kumar A, DiJohnson T, Edwards R, Walker L
J Physician Assist Educ
. 2023 Aug;
34(3):171-177.
PMID: 37548617
Introduction: When learners fail to reach milestones, educators often wonder if any warning signs could have allowed them to intervene sooner. Machine learning can predict which students are at risk...
4.
Chiorean M, Daperno M, Lees C, Bonfanti G, Soudis D, Modesto I, et al.
Adv Ther
. 2023 Jul;
40(10):4440-4459.
PMID: 37525075
Introduction: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). This post hoc analysis assessed whether various statistical techniques could predict outcomes of...
5.
Kay H, Mahoney M, Edwards R
Med Teach
. 2023 Mar;
45(8):893-905.
PMID: 36940135
Purpose: New emphasis on the assessment of health professions educators' teaching competence has led to greater use of the Objective Structured Teaching Encounter (OSTE). The purpose of this study is...
6.
Porter-Stransky K, Gibson K, VanDerKolk K, Edwards R, Graves L, Smith E, et al.
Med Sci Educ
. 2022 Dec;
33(1):63-72.
PMID: 36467744
Supplementary Information: The online version contains supplementary material available at 10.1007/s40670-022-01697-5.
7.
Atkinson J, Edwards R, Bonfanti G, Barroso J, Schnitzer T
Adv Ther
. 2022 Oct;
40(1):252-264.
PMID: 36301512
Introduction: We sought to predict analgesic response to daily oral nonsteroidal anti-inflammatory drugs (NSAIDs) or subcutaneous tanezumab 2.5 mg (every 8 weeks) at week 16 in patients with moderate-to-severe osteoarthritis,...
8.
Schnitzer T, Bonfanti G, Atkinson J, Donevan S, Viktrup L, Barroso J, et al.
Adv Ther
. 2022 Aug;
39(10):4742-4756.
PMID: 35960482
Introduction: We sought to identify and characterize distinct responder profiles among osteoarthritis (OA) subjects treated with tanezumab, nonsteroidal anti-inflammatory drugs (NSAIDs), or placebo. Methods: Subject-level data were derived from three...
9.
Nicholas J, Edwards N, Edwards R, Dellarole A, Manca L, Harlow D, et al.
Mult Scler J Exp Transl Clin
. 2022 Jul;
8(2):20552173221101150.
PMID: 35795102
Background: Increased understanding of adherence may facilitate optimal targeting of interventions. Objective: To utilize group-based trajectory modeling (GBTM) to understand longitudinal patterns of adherence and factors associated with non-adherence in...
10.
Lees C, Deuring J, Chiorean M, Daperno M, Bonfanti G, Germino R, et al.
Therap Adv Gastroenterol
. 2022 Feb;
14:17562848211054710.
PMID: 35154388
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Outcome prediction based on early treatment response, along with clinical and laboratory variables,...